Asitri Dashboard

Search Clinical Trials

The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.

Saved Searches

Choose Search
Basic Search
Targeted Search

Clinical Trials Search Results

Search History:
Count: 310
Selected: 0
NCT IDTitle
NCT03468140Pilot Trial of Eculizumab Therapy to Reduce Preservation Injury in Human Macrosteatotic Liver Transplantation
NCT06967480Early Ravulizumab Treatment Of Anti- AChR Antibody-Positive Generalized Myasthenia Gravis
NCT04355494SOLIRIS® (Eculizumab) Treatment of Participants With COVID-19
NCT05501717Safety, PK/PD, and Immunogenicity Study of SC ALXN2030 in Healthy Participants
NCT03406507A Study of Ravulizumab (ALXN1210) in Children and Adolescents With Paroxysmal Nocturnal Hemoglobinuria
NCT00122330Study Using Eculizumab in Transfusion Dependent Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients
NCT04802083COVID-19 Soliris Expanded Access Protocol
NCT05644561Evaluation of Pharmacokinetics, Pharmacodynamics, Efficacy, Safety, and Immunogenicity of Ravulizumab Administered Intravenously in Pediatric Participants With Generalized Myasthenia Gravis (gMG)
NCT01192425Paroxysmal Nocturnal Hemoglobinuria (PNH), Level of CD59 on Red and White Blood Cells in Bone Marrow Failure Syndromes
NCT02112994Safety and Efficacy Study of Sebelipase Alfa in Participants With Lysosomal Acid Lipase Deficiency
NCT07024563Study of Ravulizumab in Pediatric Participants With Primary IgAN
NCT05982938Danicopan Early Access Program
NCT06160414A Study to Investigate the Potential Drug Interactions Between ALXN2080 and Rosuvastatin and Metformin in Healthy Adult Participants
NCT01194804E07-001: Safety and Efficacy Extension Study of Eculizumab in Paroxysmal Nocturnal Hemoglobinuria Patients
NCT05288816A Study of Single and Multiple Doses of ALXN1210 in Healthy, Adult Japanese Participants
NCT04980248Study of ALXN1850 in Participants With Hypophosphatasia (HPP)
NCT00485576Safety and Efficacy Study of Eculizumab in Patients With Mild Allergic Asthma
NCT04504825A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIb AL Amyloidosis (CARES)
NCT01849562Safety, Tolerability, and Efficacy of 12-weeks of Sovaprevir, ACH-3102, and Ribavirin in Treatment-naive GT-1 HCV Participants
NCT04952545Study of ALXN2050 in Healthy Adult Participants of Japanese Descent
NCT03418389Evaluate and Monitor Physical Performance of Adults Treated With Asfotase Alfa for Hypophosphatasia
NCT04660890A Study of the Cardiac Effects of ALXN2050 in Healthy Adults
NCT05047458A Study of Single-dose ALXN2050 in Healthy Adults
NCT05578846Bioequivalence Between 180 mg and 60 mg ALXN2050 Tablets and Food Effect on ALXN2050 Pharmacokinetics
NCT03330457A Healthy Volunteer PK/PD, Safety and Tolerability Study of Andexanet After Betrixaban Dosing
NCT05109390A Study of the Drug Interactions Between Danicopan and Cyclosporine, Tacrolimus, Antacids, and Omeprazole in Healthy Adults
NCT02796885Characterisation of Adult-Onset Hypophosphatasia
NCT02128269Phase IIa Trial of ALXN1007 for the Treatment of Non-criteria Manifestations of Antiphospholipid Syndrome
NCT03759366A Phase 3 Open-Label Study of Eculizumab in Pediatric Participants With Refractory Generalized Myasthenia Gravis (gMG)
NCT01522183Atypical Hemolytic-Uremic Syndrome (aHUS) Registry
NCT01176266Open-Label Study of Asfotase Alfa in Infants and Children ≤ 5 Years of Age With Hypophosphatasia (HPP)
NCT01221181Eculizumab Therapy for Dense Deposit Disease and C3 Nephropathy
NCT04422431Copper Concentration & Histopathologic Changes in Liver Biopsy in Participants With Wilson Disease Treated With ALXN1840
NCT00844844Open Label Controlled Trial of Eculizumab in Adolescent Patients With Plasma Therapy-Resistant aHUS
NCT01522170aHUS Observational Long Term Follow-Up
NCT02376751An Expanded Access Protocol for Sebelipase Alfa for Patients With Lysosomal Acid Lipase Deficiency
NCT02614898Evaluation of Potential Predictors of Disease Progression in Participants With Atypical Hemolytic Uremic Syndrome (aHUS) Including Genetics, Biomarkers, and Treatment
NCT01106027Dosing Regimen of Eculizumab Added to Conventional Treatment in Positive Crossmatch Deceased Donor Kidney Transplant
NCT01194973An Open-label, Multi-center Clinical Trial of Eculizumab in Adult Patients With Atypical Hemolytic-uremic Syndrome
NCT00867932Eculizumab Pharmacokinetics/Pharmacodynamics Study in Pediatric/Adolescent Paroxysmal Nocturnal Hemoglobinuria (PNH)
NCT04743804Ravulizumab in Thrombotic Microangiopathy Associated With a Trigger
NCT07213583Study of Re-Treatment With ALXN2220 in Patients With ATTR-CM
NCT03218241Single Ascending Dose Study of PRT064445, a Factor Xa (fXa) Inhibitor Antidote
NCT04889690Study of Multiple Doses of Danicopan in Healthy Participants
NCT03723512Non-contrast Enhanced MRI in Patients With C3 Glomerulopathy (C3G) or Immune-complex Membranoproliferative Glomerulonephritis (IC-MPGN) Enrolled in the ACH471-205 Study
NCT00312039Study of Once Daily Elvucitabine Versus Lamivudine in Participants With a Documented M184V Mutation
NCT06724809Efficacy, Safety, PK, PD, and ADA of Eculizumab in Chinese Adults With NMOSD
NCT06079372Phase 3 Study of ALXN1850 in Pediatric Participants With HPP Previously Treated With Asfotase Alfa
NCT06398158Study of the Clinical and Radiological Impact of Ravulizumab in People With Neuromyelitis Optica Spectrum Disorder
NCT05314231Safety and Pharmacokinetic Study of Subcutaneous ALXN1720 in Participants With Proteinuria